• Deborah Byrd - Life’s building blocks found in Orion Nebula:

    https://earthsky.org/space/lifes-building-blocks-found-in-orion-nebula/

    #OrionNebula #OrionBar #Biomarker #Carbon #MethylCation #CH3Plus #D203506 #RedDwarf #JamesWebb #SpaceTelescope #JWST #NASA #OrganicChemistry #Chemistry #Astronomy
    Deborah Byrd - Life’s building blocks found in Orion Nebula: https://earthsky.org/space/lifes-building-blocks-found-in-orion-nebula/ #OrionNebula #OrionBar #Biomarker #Carbon #MethylCation #CH3Plus #D203506 #RedDwarf #JamesWebb #SpaceTelescope #JWST #NASA #OrganicChemistry #Chemistry #Astronomy
    0 Comments 0 Shares 3530 Views
  • Massimo Luciani - Uracil and vitamin B3 found in samples from asteroid Ryugu:

    https://english.tachyonbeam.com/2023/03/23/uracil-and-vitamin-b3-found-in-samples-from-asteroid-ryugu/

    #Asteroid #Ryugu #Uracil #Niacin #VitaminB3 #Organics #Biomarkers #JAXA #Hayabusa2 #SampleReturn #Hokkaido #Astrobiology #Astronomy

    Massimo Luciani - Uracil and vitamin B3 found in samples from asteroid Ryugu: https://english.tachyonbeam.com/2023/03/23/uracil-and-vitamin-b3-found-in-samples-from-asteroid-ryugu/ #Asteroid #Ryugu #Uracil #Niacin #VitaminB3 #Organics #Biomarkers #JAXA #Hayabusa2 #SampleReturn #Hokkaido #Astrobiology #Astronomy
    ENGLISH.TACHYONBEAM.COM
    Uracil and vitamin B3 found in samples from asteroid Ryugu
    An article published in the journal 'Nature Communications' reports the discovery of uracil, one of the bases of RNA, and niacin, i.e. vitamin B3, in the...
    0 Comments 0 Shares 2256 Views
  • Abstract 10712: Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning

    A Peer Reviewed Journal BTW
    Doctor Vernon Coleman says that THIS STUDY being released shows that the #mRNA #Vaccine is a KILLER and anyone still injecting it into people is a #Murderer!

    Abstract
    Our group has been using the PLUS Cardiac Test (GD Biosciences, Inc, Irvine, CA) a clinically validated measurement of multiple protein biomarkers which generates a score predicting the 5 yr risk (percentage chance) of a new Acute Coronary Syndrome (ACS). The score is based on changes from the norm of multiple protein biomarkers including IL-16, a proinflammatory cytokine, soluble Fas, an inducer of apoptosis, and Hepatocyte Growth Factor (HGF)which serves as a marker for chemotaxis of T-cells into epithelium and cardiac tissue, among other markers. Elevation above the norm increases the PULS score, while decreases below the norm lowers the PULS score.The score has been measured every 3-6 months in our patient population for 8 years. Recently, with the advent of the mRNA COVID 19 vaccines (vac) by Moderna and Pfizer, dramatic changes in the PULS score became apparent in most patients.This report summarizes those results. A total of 566 pts, aged 28 to 97, M:F ratio 1:1 seen in a preventive cardiology practice had a new PULS test drawn from 2 to 10 weeks following the 2nd COVID shot and was compared to the previous PULS score drawn 3 to 5 months previously pre- shot. Baseline IL-16 increased from 35=/-20 above the norm to 82 =/- 75 above the norm post-vac; sFas increased from 22+/- 15 above the norm to 46=/-24 above the norm post-vac; HGF increased from 42+/-12 above the norm to 86+/-31 above the norm post-vac. These changes resulted in an increase of the PULS score from 11% 5 yr ACS risk to 25% 5 yr ACS risk. At the time of this report, these changes persist for at least 2.5 months post second dose of vac.We conclude that the mRNA vacs dramatically increase inflammation on the endothelium and T cell infiltration of cardiac muscle and may account for the observations of increased thrombosis, cardiomyopathy, and other vascular events following vaccination.

    https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712
    Abstract 10712: Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning A Peer Reviewed Journal BTW Doctor Vernon Coleman says that THIS STUDY being released shows that the #mRNA #Vaccine is a KILLER and anyone still injecting it into people is a #Murderer! Abstract Our group has been using the PLUS Cardiac Test (GD Biosciences, Inc, Irvine, CA) a clinically validated measurement of multiple protein biomarkers which generates a score predicting the 5 yr risk (percentage chance) of a new Acute Coronary Syndrome (ACS). The score is based on changes from the norm of multiple protein biomarkers including IL-16, a proinflammatory cytokine, soluble Fas, an inducer of apoptosis, and Hepatocyte Growth Factor (HGF)which serves as a marker for chemotaxis of T-cells into epithelium and cardiac tissue, among other markers. Elevation above the norm increases the PULS score, while decreases below the norm lowers the PULS score.The score has been measured every 3-6 months in our patient population for 8 years. Recently, with the advent of the mRNA COVID 19 vaccines (vac) by Moderna and Pfizer, dramatic changes in the PULS score became apparent in most patients.This report summarizes those results. A total of 566 pts, aged 28 to 97, M:F ratio 1:1 seen in a preventive cardiology practice had a new PULS test drawn from 2 to 10 weeks following the 2nd COVID shot and was compared to the previous PULS score drawn 3 to 5 months previously pre- shot. Baseline IL-16 increased from 35=/-20 above the norm to 82 =/- 75 above the norm post-vac; sFas increased from 22+/- 15 above the norm to 46=/-24 above the norm post-vac; HGF increased from 42+/-12 above the norm to 86+/-31 above the norm post-vac. These changes resulted in an increase of the PULS score from 11% 5 yr ACS risk to 25% 5 yr ACS risk. At the time of this report, these changes persist for at least 2.5 months post second dose of vac.We conclude that the mRNA vacs dramatically increase inflammation on the endothelium and T cell infiltration of cardiac muscle and may account for the observations of increased thrombosis, cardiomyopathy, and other vascular events following vaccination. https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712
    Like
    1
    0 Comments 0 Shares 859 Views
  • Biomarkers Market- What will be the Short-term Impact of Coronavirus? Please visit: https://www.fortunebusinessinsights.com/biomarkers-market-102173
    Biomarkers Market- What will be the Short-term Impact of Coronavirus? Please visit: https://www.fortunebusinessinsights.com/biomarkers-market-102173
    WWW.FORTUNEBUSINESSINSIGHTS.COM
    Global Biomarkers Market Size, Share | Report [2019-2026]
    The global biomarkers market size stood at USD 39.10 billion in 2018 and is projected to reach USD 97.51 billion by 2026, exhibiting a CAGR of 12.1% during the forecast period.
    0 Comments 0 Shares 534 Views
  • Coronavirus Outbreak: BiomarkerS Industry Fights Back with Well-defined Business Strategies https://www.fortunebusinessinsights.com/biomarkers-market-102173
    Coronavirus Outbreak: BiomarkerS Industry Fights Back with Well-defined Business Strategies https://www.fortunebusinessinsights.com/biomarkers-market-102173
    WWW.FORTUNEBUSINESSINSIGHTS.COM
    Global Biomarkers Market Size, Share | Report [2019-2026]
    The global biomarkers market size stood at USD 39.10 billion in 2018 and is projected to reach USD 97.51 billion by 2026, exhibiting a CAGR of 12.1% during the forecast period.
    0 Comments 0 Shares 649 Views
  • Coronavirus Outbreak: BiomarkerS Industry Fights Back with Well-defined Business Strategies Click here to get the short-term and long-term impact of COVID-19 on this Biomarkers Market.
    Please visit: https://www.fortunebusinessinsights.com/biomarkers-market-102173
    Coronavirus Outbreak: BiomarkerS Industry Fights Back with Well-defined Business Strategies Click here to get the short-term and long-term impact of COVID-19 on this Biomarkers Market. Please visit: https://www.fortunebusinessinsights.com/biomarkers-market-102173
    WWW.FORTUNEBUSINESSINSIGHTS.COM
    Global Biomarkers Market Size, Share | Report [2019-2026]
    The global biomarkers market size stood at USD 39.10 billion in 2018 and is projected to reach USD 97.51 billion by 2026, exhibiting a CAGR of 12.1% during the forecast period.
    0 Comments 0 Shares 635 Views
  • Cancer Biomarkers Market: Government-supported Awareness Programs will help Market Gain Traction, says Fortune Business Insights™
    The global cancer biomarkers market size isforecastto reach USD 48.20billion by 2026 on account of the increasing popularity of personalized treatment for cancer worldwide. Biomarkers help to detect cancer at an early stage and facilitate noninvasive diagnosis at high-speed by utilizing different proteomic and genomic markers.As per a recently published report by Fortune Business insights™ titled, “Cancer Biomarkers Market Size, Share & Industry Analysis, By Cancer Type (Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer And Others), By Biomarker Type (PSA, HER-2, EGFR,KRAS, and others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals &Specialty Clinics, and Others), and Regional Forecast, 2019-2026,” the market size was USD 18.94 billion in 2018 and will exhibit a CAGR of 12.4% between 2019 and 2026.

    Request Sample PDF: https://www.fortunebusinessinsights.com/enquiry/sample/cancer-biomarkers-market-100630


    Report Highlights

    The report offers a comprehensive overview of the market and its prime growth trajectories, such as drivers, restraints, challenges, and opportunities. It throws light on recent oncology biomarker market trends, key industry developments, and other interesting insights. The report emphasizes on the table of segmentation based on factors such as cancer type, biomarker type, end user, and geography. The report discusses the list of players operating in the market and the prime strategies adopted by them to gain a competitive edge in the market. For more information on the report, log on to the company website.

    The COVID-19 pandemic has caused huge losses for several companies by halting their manufacturing processes. The governments of various companies are persistently striving to prevent the transmission of coronavirus by promoting social distancing and sanitization measures. Our reports would help you in gaining more insights into the effects of COVID-19 on every market.


    Competitive Landscape:

    Substantial Investment in Research and Development of Novel Therapeutics to Escalate Market Competition

    Major companies in the Global Cancer Biomarkers Market are increasingly focusing on research and development activities to create new and innovative products to stay ahead of the competition. Staying on top of market trends & drivers is crucial for decision-makers to hold this emerging opportunity. The study provides information on market trends and development, drivers, capacities, technologies, and the changing investment structure of the Healthcare Industry.

    List of Key Cancer Biomarker MarketManufacturers:

    • Myriad RBM
    • Abbott
    • F. Hoffmann-La Roche Ltd.
    • BioVision Inc.
    • Thermo Fisher Scientific
    • R&D System
    • Bio-Rad Laboratories, Inc.
    • Sino Biological Inc.
    • CENTOGENE N.V.
    • Sino Biological Inc.
    • Axon Medchem
    Cancer Biomarkers Market: Government-supported Awareness Programs will help Market Gain Traction, says Fortune Business Insights™ The global cancer biomarkers market size isforecastto reach USD 48.20billion by 2026 on account of the increasing popularity of personalized treatment for cancer worldwide. Biomarkers help to detect cancer at an early stage and facilitate noninvasive diagnosis at high-speed by utilizing different proteomic and genomic markers.As per a recently published report by Fortune Business insights™ titled, “Cancer Biomarkers Market Size, Share & Industry Analysis, By Cancer Type (Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer And Others), By Biomarker Type (PSA, HER-2, EGFR,KRAS, and others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals &Specialty Clinics, and Others), and Regional Forecast, 2019-2026,” the market size was USD 18.94 billion in 2018 and will exhibit a CAGR of 12.4% between 2019 and 2026. Request Sample PDF: https://www.fortunebusinessinsights.com/enquiry/sample/cancer-biomarkers-market-100630 Report Highlights The report offers a comprehensive overview of the market and its prime growth trajectories, such as drivers, restraints, challenges, and opportunities. It throws light on recent oncology biomarker market trends, key industry developments, and other interesting insights. The report emphasizes on the table of segmentation based on factors such as cancer type, biomarker type, end user, and geography. The report discusses the list of players operating in the market and the prime strategies adopted by them to gain a competitive edge in the market. For more information on the report, log on to the company website. The COVID-19 pandemic has caused huge losses for several companies by halting their manufacturing processes. The governments of various companies are persistently striving to prevent the transmission of coronavirus by promoting social distancing and sanitization measures. Our reports would help you in gaining more insights into the effects of COVID-19 on every market. Competitive Landscape: Substantial Investment in Research and Development of Novel Therapeutics to Escalate Market Competition Major companies in the Global Cancer Biomarkers Market are increasingly focusing on research and development activities to create new and innovative products to stay ahead of the competition. Staying on top of market trends & drivers is crucial for decision-makers to hold this emerging opportunity. The study provides information on market trends and development, drivers, capacities, technologies, and the changing investment structure of the Healthcare Industry. List of Key Cancer Biomarker MarketManufacturers: • Myriad RBM • Abbott • F. Hoffmann-La Roche Ltd. • BioVision Inc. • Thermo Fisher Scientific • R&D System • Bio-Rad Laboratories, Inc. • Sino Biological Inc. • CENTOGENE N.V. • Sino Biological Inc. • Axon Medchem
    WWW.FORTUNEBUSINESSINSIGHTS.COM
    Request a Sample - Cancer Biomarkers Market Size, Share and Global Industry Trend Forecast till 2025
    The global cancer biomarkers market size stood at USD 18.94 billion in 2018 and is projected to reach USD 48.20 billion by 2026, exhibiting a CAGR of 12.4% during the forecast period.
    Like
    1
    0 Comments 0 Shares 906 Views
  • MicroRNAs in Human Cancers.

    George Calin is a principal investigator with the MD Anderson Cancer Center at the University of Texas. He specializes in how non-coding RNAs impact disease and virus mechanisms, specifically the role of microRNAs in human cancers.

    Listen to it here: https://bit.ly/33x5vxt

    Episode also available on Apple Podcasts: apple.co/30PvU9C
    .
    .
    .
    .
    #cancer #genes #genetics #Virus #RNA #microRNA #noncodingRNA #genomics #biomarkers #Findinggeniuspodcast #Healthpodcast #InternalMedicinepodcast #Biosciencespodcast
    MicroRNAs in Human Cancers. George Calin is a principal investigator with the MD Anderson Cancer Center at the University of Texas. He specializes in how non-coding RNAs impact disease and virus mechanisms, specifically the role of microRNAs in human cancers. Listen to it here: https://bit.ly/33x5vxt Episode also available on Apple Podcasts: apple.co/30PvU9C . . . . #cancer #genes #genetics #Virus #RNA #microRNA #noncodingRNA #genomics #biomarkers #Findinggeniuspodcast #Healthpodcast #InternalMedicinepodcast #Biosciencespodcast
    0 Comments 0 Shares 765 Views
  • Searching for Alzheimer’s Biomarkers.

    David Wishart is a professor in the Departments of Biological Sciences and Computing Science at the University of Alberta (Wishart Lab). He works with bioinformatics software, nanobiology, and machine learning in healthcare to fine tune the use of biomarkers in diagnostics.

    Listen to it here: https://bit.ly/3nP2CkS

    Episode also available on Apple Podcasts: apple.co/30PvU9C
    .
    .
    .
    .
    #MachineLearning #BloodTest #Alzheimer #Computing #nanobiology #syntheticbiology #bioinformatics #metabolomics #Findinggeniuspodcast #Healthpodcast #InternalMedicinepodcast #Biosciencespodcast
    Searching for Alzheimer’s Biomarkers. David Wishart is a professor in the Departments of Biological Sciences and Computing Science at the University of Alberta (Wishart Lab). He works with bioinformatics software, nanobiology, and machine learning in healthcare to fine tune the use of biomarkers in diagnostics. Listen to it here: https://bit.ly/3nP2CkS Episode also available on Apple Podcasts: apple.co/30PvU9C . . . . #MachineLearning #BloodTest #Alzheimer #Computing #nanobiology #syntheticbiology #bioinformatics #metabolomics #Findinggeniuspodcast #Healthpodcast #InternalMedicinepodcast #Biosciencespodcast
    0 Comments 0 Shares 1943 Views
  • Masks are priming the lungs for inflammation and lung cancer pathology

    A study published in the journal Cancer Discovery finds that lung cancer progresses when the lungs are forced to regurgitate microbes. Prolonged mask use creates a moist environment that cultivates microbes. This toxic environment not only forces the person to regurgitate their own wastes, but also inundates the lungs with microbes that cause a toxic environment that feeds lung cancer.

    The researchers found that the lungs are not just a sterile environment. When microbes inundate the lungs, they can active an immune response. This causes inflammatory proteins such as the cytokine IL-17 to appear.

    Microbes that are normally found in the mouth can make their way into the lungs. “Given the known impact of IL-17 and inflammation on lung cancer, we were interested in determining if the enrichment of oral commensals in the lungs could drive an IL-17-type inflammation and influence lung cancer progression and prognosis,” said Leopoldo Segal, Director of the Lung Microbiome Program and Associate Professor of Medicine, New York University Grossman School of Medicine. (Related: Masked schoolchildren are harmed physically, psychologically, behaviorally and suffer from 24 distinct health issues.)

    Masks cultivate and enrich microbes that infiltrate the lungs and cause immune suppression

    The research team used diagnostic clinical bronchoscopies to analyze the lung microbiomes of 83 untreated adult patients who were diagnosed with lung cancer. They identified the composition of each microbial environment and documented which genes were expressed as a result. They found that lung tissue from patients with advanced state lung cancer (stages 3b-4) was more enriched with microbes than lung tissue of patients who had early stage disease. This increased enrichment of oral bacteria in the lungs was also associated with decreased chance of survival, no matter the stage of tumors. The bacteria colonies that caused the most damage was Veillonella, Prevotella, and Streptococcus bacteria, all of which are more readily cultivated in a mask. Tumor progression was associated with the enrichment of Veillonella, Prevotella, Streptococcus, and Rothia bacteria. The cultivated microbes infiltrate the lungs and affect genetic expression, namely the p53, PI3K/PTEN, ERK, and IL-6/IL-8 signaling pathways.

    In further evaluation, the cultivation of Veillonella parvula in the lungs of mice led to expression of inflammatory proteins, increased expression of IL-17, and the presence of immune suppressing cells. “Given the results of our study, it is possible that changes to the lung microbiome could be used as a biomarker to predict prognosis or to stratify patients for treatment,” said Segal. Prolonged mask wearing not only puts strain on the heart and lungs but also cultivates a microbial environment that is more likely to infiltrate the lungs and create an environment of cancer.
    Masks are priming the lungs for inflammation and lung cancer pathology A study published in the journal Cancer Discovery finds that lung cancer progresses when the lungs are forced to regurgitate microbes. Prolonged mask use creates a moist environment that cultivates microbes. This toxic environment not only forces the person to regurgitate their own wastes, but also inundates the lungs with microbes that cause a toxic environment that feeds lung cancer. The researchers found that the lungs are not just a sterile environment. When microbes inundate the lungs, they can active an immune response. This causes inflammatory proteins such as the cytokine IL-17 to appear. Microbes that are normally found in the mouth can make their way into the lungs. “Given the known impact of IL-17 and inflammation on lung cancer, we were interested in determining if the enrichment of oral commensals in the lungs could drive an IL-17-type inflammation and influence lung cancer progression and prognosis,” said Leopoldo Segal, Director of the Lung Microbiome Program and Associate Professor of Medicine, New York University Grossman School of Medicine. (Related: Masked schoolchildren are harmed physically, psychologically, behaviorally and suffer from 24 distinct health issues.) Masks cultivate and enrich microbes that infiltrate the lungs and cause immune suppression The research team used diagnostic clinical bronchoscopies to analyze the lung microbiomes of 83 untreated adult patients who were diagnosed with lung cancer. They identified the composition of each microbial environment and documented which genes were expressed as a result. They found that lung tissue from patients with advanced state lung cancer (stages 3b-4) was more enriched with microbes than lung tissue of patients who had early stage disease. This increased enrichment of oral bacteria in the lungs was also associated with decreased chance of survival, no matter the stage of tumors. The bacteria colonies that caused the most damage was Veillonella, Prevotella, and Streptococcus bacteria, all of which are more readily cultivated in a mask. Tumor progression was associated with the enrichment of Veillonella, Prevotella, Streptococcus, and Rothia bacteria. The cultivated microbes infiltrate the lungs and affect genetic expression, namely the p53, PI3K/PTEN, ERK, and IL-6/IL-8 signaling pathways. In further evaluation, the cultivation of Veillonella parvula in the lungs of mice led to expression of inflammatory proteins, increased expression of IL-17, and the presence of immune suppressing cells. “Given the results of our study, it is possible that changes to the lung microbiome could be used as a biomarker to predict prognosis or to stratify patients for treatment,” said Segal. Prolonged mask wearing not only puts strain on the heart and lungs but also cultivates a microbial environment that is more likely to infiltrate the lungs and create an environment of cancer.
    0 Comments 0 Shares 409 Views
More Results
Sponsored

We are, so far, 80% funded for April. I am matching donations dollar for dollar this month. Thanks to everyone who helped out. 🥰

Xephula monthly operating expenses for 2024 - Server: $143/month - Backup Software: $6/month - Object Storage: $6/month - SMTP Service: $10/month - Stripe Processing Fees: ~$10/month - Total: $175/month

Xephula Funding Meter

Please Donate Here